Image

1-step HRM Analysis: MicroSight® MSI

Microsatellite instability (MSI) is a genomic alteration in the length of microsatellites provoked by a deficient DNA mismatch repair system. MSI is known to occur in several types of cancer e.g., colorectal cancer (CRC), which accounts for 10.7% of newly diagnosed cancers globally (3’rd most occurring) according to World Cancer Research Fund’s data (2020). Identification of MSI in tumours is important as a predictive factor of response to different therapies, in particular to immune checkpoint inhibitors, and accordingly the need for MSI analysis of these patients has significantly increased. The MicroSight® MSI 1-step HRM Analysis assay analyses five well-described mononucleotide microsatellite sequences: BAT25, BAT26, NR22, NR24, and MONO27, by Real-Time PCR and HRM. The assay evaluates microsatellite length of patient tumour DNA to patient non-tumour DNA or a universal reference, which makes it a valuable stratification tool for assisting cancer treatment planning. After the Real-Time PCR and HRM, a semi-automatic analysis will be made by the instrument software giving objective results in less than 2 hours.

Advantages of MicroSight® MSI: 

  • Results in less than two hours
  • Minimal hands-on time
  • Objective analysis – No biased data interpretation
  • One instrument analysis – Low risk of cross contamination
Image

Assay | CANCER DIAGNOSTICS: SensiScreen®

Combining simplex and multiplexing capabilities with PentaBase’s unique DNA technologies and open platform designs, SensiScreen® assays deliver profound sensitivity and flexibility in the analysis of somatic mutations, to aid in the selection of proper cancer treatment based on the patient’s mutational status.

Common cancers including colorectal cancer, lung cancer and malignant melanoma are characterized by the accumulation of somatic mutations, some of which  are known to affect a patient’s response to cancer treatments. SensiScreen® qPCR-based assays provide fast and reliable somatic mutation detection to support rapid initiation of the optimal cancer treatment.

The assay is available in 2 formats:

  • Analysis of liquid biopsies
  • Analysis of FFPE biopsies
Image

Assays | Cancer diagnosis and stratification: PlentiPlex™ Mastocytosis

PlentiPlexMastocytosis assay is intended for the detection of the KIT D816V mutation, which is among the WHO criteria for the diagnosis of mastocytosis. PlentiPlex™ Mastocytosis Assay utilises PentaBase’s unique DNA chemistry, known as Intercalating Nucleic Acid (INA), which vastly increases both affinity and specificity of assay oligonucleotides towards the target region compared to assays based on standard DNA chemistries.  

Advantages of PlentiPlex™ Mastocytosis: 

  • The Assay follows WHO criteria
  • Applicable for large biopsies
  • 2 formats (Ready-to-use & Dispense ready)
  • Enables further personalised cancer treatment
Image

Assays | Cancer diagnosis and stratification: PlentiPlex™ MSI

PlentiPlex™ MSI assays are intended for evaluation of impaired mismatch repair (MMR) and the resulting microsatellite instability affecting prognosis and selection of treatment in cancer patients. PlentiPlex™ MSI assays offer two different multiplexed MSI assays for the length analysis of five microsatellite loci. This makes PlentiPlex™ MSI assays valuable stratification tools for assisting cancer treatment planning.

Advantages of PlentiPlex™ MSI:

  • Simple MSI stratification of solid tumors for treatment guidance
  • Simplified four-step workflow
  • Well-known validated loci
  • Minimal hands-on time
Image

Waldenström Lymphoma qPCR Assay: PlentiPlex™ MYD88

A highly sensitivity qPCR assay for detection of the MYD88 L265P mutation, used as an aid in the stratification of lymphoma subtypes. 

PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay utilises PentaBase’s unique DNA chemistry, known as Intercalating Nucleic Acid (INA™) which vastly increases both affinity and specificity of assay oligonucleotides towards the target region compared to assays based on standard DNA chemistries.

The obtained results of PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay are intended for identification of the presence of the MYD88 L265P, facilitating discrimination between Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) and non-Hodgkin lymphoma

Advantages of PlentiPlex™ MYD88 :

  • Results in less than two hours
  • Open platform design
  • High sensitivity due to INA™ chemistry
  • Minimal hands-on time

AL-Labor

Über 20 Jahre Erfahrung in der
Labortechnik, Molekular- & Zellbiologie

Image

Auf uns können
Sie sich verlassen!

© 2023, AL-Labortechnik & Diagnostik GmbH | Webagentur: EDBS GmbH

Adresse

Friedlmühle 7
3311 Zeillern - Amstetten

Kontaktinfos

Tel. +43 (0)7472/23423-0
Fax +43 (0)7472/23423-4

Mo.-Do.: 8:30 – 16:00 Uhr | Fr.: 8:30 – 12:00 Uhr

office@al-labor.at